Home › Companies › SERES THERAPEUTICS INC. › 2023-2024

SERES THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and SERES THERAPEUTICS INC.’s Form 8-K, filed 2024-04-08 (Item 5.07 on EDGAR). Page generated 04 October 2026.

  • 7Ballot items
  • 112Asset managers
  • 865Fund votes
  • 2024-04-04Meeting date

Proxy season: 2023-2024

Explore SERES THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by SERES THERAPEUTICS INC.

These tallies are SERES THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-04-08 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SERES THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-04-04
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Paul R. Biondi 53,477,829---- 29,111,82921,764,552 Majority: yes
Elect Director: Kurt C. Graves 51,107,660---- 31,481,99821,764,552 Majority: yes
Item 2 - Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. 100,843,5502,910,775599,885 --0 Majority: yes
Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers. 52,923,69929,004,971660,988 --21,764,552 Majority: yes
Item 4 - Approval of an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 240,000,000 to 360,000,000 shares. 81,471,93421,346,1401,536,136 --0 Majority: yes
Item 5 - Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Annual Meeting to approve Item 4. 83,248,72919,390,1951,715,286 --0 Majority: yes
Item 6 – A stockholder proposal on Simple Majority Vote. 52,117,62429,641,877830,157 --21,764,552 Majority: yes

Source: SERES THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-04-08 — read the filing on EDGAR.

How asset managers voted at the SERES THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 112 asset managers that disclosed a SERES THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Approval, on an advisory (non- binding) basis, of the compensation of our named executive officers.

COMPENSATIONMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

65% Majority: yes · of votes cast

FOR 65%AGAINST 35%
FOR: 52,923,699AGAINST: 29,004,971

SERES THERAPEUTICS INC.’s own tally for this item (“Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.”): 52,923,699 for, 29,004,971 against, per its Form 8-K filed 2024-04-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 151,009,462 outstanding shares: 35% for, 19% against (54.3% of the company cast a for/against vote).

The 110 asset managers below cast 60% of the shares they voted on this item FOR (42,999,188 for, 29,216,118 against).

FOR 60%AGAINST 40%
FOR: 42,999,188 (59.5%)AGAINST: 29,216,118 (40.5%)
Largest asset managers voting on “Approval, on an advisory (non- binding) basis, of the compensation of our named executive officers.” at SERES THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity1,030,74828,978,827 00Against
Flagship Pioneering Inc.23,117,0450 00For
Vanguard4,196,2240 00For
Hudson Bay Capital Management LP4,048,1790 00For
BlackRock3,477,4595,136 00For
GEODE CAPITAL MANAGEMENT, LLC1,118,4820 00For
State Street1,052,145130 00For
Charles Schwab781,7060 00For
Woodline Partners LP698,9990 00For
MELLON INVESTMENTS Corp485,9150 00For
Handelsbanken Fonder AB329,9260 00For
Point72294,3270 00For
SIT MUTUAL FUNDS INC246,7750 00For
Graham Capital Management, L.P.234,3430 00For
T. Rowe Price203,0060 00For
DE Shaw173,8510 00For
Equitable167,1240 00For
BRIDGEWAY FUNDS INC0150,000 00Against
AllianceBernstein127,6600 00For
Northern Trust96,071149 00For
SIT INVESTMENT ASSOCIATES INC95,4250 00For
Lincoln Financial80,0000 00For
Janney Montgomery Scott LLC75,0980 00For
Voya66,1220 00For
PRINCIPAL GLOBAL INVESTORS61,0760 00For

Showing the 25 largest of 110 asset managers. See all 110 in the interactive database.

2. A STOCKHOLDER PROPOSAL ON SIMPLE MAJORITY VOTE, IF PROPERLY PRESENTED.

CORPORATE GOVERNANCEMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

64% Majority: yes · of votes cast

FOR 64%AGAINST 36%
FOR: 52,117,624AGAINST: 29,641,877

SERES THERAPEUTICS INC.’s own tally for this item (“Item 6 – A stockholder proposal on Simple Majority Vote.”): 52,117,624 for, 29,641,877 against, per its Form 8-K filed 2024-04-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 151,009,462 outstanding shares: 35% for, 20% against (54.1% of the company cast a for/against vote).

The 32 asset managers below cast 100% of the shares they voted on this item FOR (18,253,814 for, 0 against).

FOR 100%
FOR: 18,253,814 (100.0%)
Largest asset managers voting on “A STOCKHOLDER PROPOSAL ON SIMPLE MAJORITY VOTE, IF PROPERLY PRESENTED.” at SERES THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity11,633,7830 00For
Vanguard4,073,1900 00For
BlackRock1,168,1140 00For
Charles Schwab390,8530 00For
SIT MUTUAL FUNDS INC246,7750 00For
Equitable167,1240 00For
BRIDGEWAY FUNDS INC150,0000 00For
Lincoln Financial80,0000 00For
QUANTITATIVE MASTER SERIES LLC54,7300 00For
Principal Exchange-Traded Funds48,9170 00For
Northern Trust43,6230 00For
Pacific Life34,8780 00For
Voya33,0610 00For
Bridge Builder Trust24,4680 00For
John Hancock18,4420 00For
DWS15,0650 00For
Victory Capital12,9480 00For
Principal12,1590 00For
AIG/SunAmerica11,3650 00For
State Street8,4620 00For
Calvert8,0330 00For
Morgan Stanley3,8660 00For
ProShares3,7550 00For
PENN SERIES FUNDS INC3,6000 00For
SEI2,3000 00For

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

3. APPROVAL OF AN ADJOURNMENT OF THE ANNUAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES AT THE TIME OF THE ANNUAL MEETING TO APPROVE PROPOSAL 4.

CORPORATE GOVERNANCEMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%AGAINST 19%
FOR: 83,248,729AGAINST: 19,390,195

SERES THERAPEUTICS INC.’s own tally for this item (“Item 5 - Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Annual Meeting to approve Item 4.”): 83,248,729 for, 19,390,195 against, per its Form 8-K filed 2024-04-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 151,009,462 outstanding shares: 55% for, 13% against (68% of the company cast a for/against vote).

The 32 asset managers below cast 99.4% of the shares they voted on this item FOR (18,159,918 for, 93,896 against).

FOR 99.4%
FOR: 18,159,918 (99.5%)AGAINST: 93,896 (0.5%)
Largest asset managers voting on “APPROVAL OF AN ADJOURNMENT OF THE ANNUAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT” at SERES THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity11,633,7830 00For
Vanguard4,073,1900 00For
BlackRock1,168,1140 00For
Charles Schwab390,8530 00For
SIT MUTUAL FUNDS INC246,7750 00For
Equitable167,1240 00For
BRIDGEWAY FUNDS INC150,0000 00For
Lincoln Financial080,000 00Against
QUANTITATIVE MASTER SERIES LLC54,7300 00For
Principal Exchange-Traded Funds48,9170 00For
Northern Trust43,6230 00For
Pacific Life34,8780 00For
Voya33,0610 00For
Bridge Builder Trust24,4680 00For
John Hancock18,4420 00For
DWS15,0650 00For
Victory Capital12,9480 00For
Principal12,1590 00For
AIG/SunAmerica11,3650 00For
State Street08,462 00Against
Calvert8,0330 00For
Morgan Stanley3,8660 00For
ProShares3,7550 00For
PENN SERIES FUNDS INC03,600 00Against
SEI2,3000 00For

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

4. APPROVAL OF AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 240,000,000 TO 360,000,000.

CAPITAL STRUCTUREMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%AGAINST 21%
FOR: 81,471,934AGAINST: 21,346,140

SERES THERAPEUTICS INC.’s own tally for this item (“Item 4 - Approval of an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 240,000,000 to 360,000,000 shares.”): 81,471,934 for, 21,346,140 against, per its Form 8-K filed 2024-04-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 151,009,462 outstanding shares: 54.0% for, 14% against (68% of the company cast a for/against vote).

The 32 asset managers below cast 100% of the shares they voted on this item FOR (18,253,814 for, 0 against).

FOR 100%
FOR: 18,253,814 (100.0%)
Largest asset managers voting on “APPROVAL OF AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHA” at SERES THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity11,633,7830 00For
Vanguard4,073,1900 00For
BlackRock1,168,1140 00For
Charles Schwab390,8530 00For
SIT MUTUAL FUNDS INC246,7750 00For
Equitable167,1240 00For
BRIDGEWAY FUNDS INC150,0000 00For
Lincoln Financial80,0000 00For
QUANTITATIVE MASTER SERIES LLC54,7300 00For
Principal Exchange-Traded Funds48,9170 00For
Northern Trust43,6230 00For
Pacific Life34,8780 00For
Voya33,0610 00For
Bridge Builder Trust24,4680 00For
John Hancock18,4420 00For
DWS15,0650 00For
Victory Capital12,9480 00For
Principal12,1590 00For
AIG/SunAmerica11,3650 00For
State Street8,4620 00For
Calvert8,0330 00For
Morgan Stanley3,8660 00For
ProShares3,7550 00For
PENN SERIES FUNDS INC3,6000 00For
SEI2,3000 00For

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

5. Election of Directors: Kurt C. Graves

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

62% Majority: yes · of votes cast

FOR 62%WITHHELD 38%
FOR: 51,107,660WITHHELD: 31,481,998

SERES THERAPEUTICS INC.’s own tally for this item (“Elect Director: Kurt C. Graves”): 51,107,660 for, 31,481,998 withheld, per its Form 8-K filed 2024-04-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 151,009,462 outstanding shares: 34% for, 21% withheld (54.7% of the company cast a for/withheld vote).

The 32 asset managers below cast 100% of the shares they voted on this item FOR (6,843,861 for, 0 against).

FOR 37%ABSTAIN 63%
FOR: 6,843,861 (37.5%)ABSTAIN: 11,409,953 (62.5%)
Largest asset managers voting on “Election of Directors: Kurt C. Graves” at SERES THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity1,018,2480 10,615,5350Abstain
Vanguard4,073,1900 00For
BlackRock1,168,1140 00For
Charles Schwab390,8530 00For
SIT MUTUAL FUNDS INC00 246,7750Abstain
Equitable39,4640 127,6600Abstain
BRIDGEWAY FUNDS INC00 150,0000Abstain
Lincoln Financial00 80,0000Abstain
QUANTITATIVE MASTER SERIES LLC54,7300 00For
Principal Exchange-Traded Funds00 48,9170Abstain
Northern Trust00 43,6230Abstain
Pacific Life34,8780 00For
Voya33,0610 00For
Bridge Builder Trust24,4680 00For
John Hancock00 18,4420Abstain
DWS00 15,0650Abstain
Victory Capital00 12,9480Abstain
Principal00 12,1590Abstain
AIG/SunAmerica00 11,3650Abstain
State Street00 8,4620Abstain
Calvert00 8,0330Abstain
Morgan Stanley3,8660 00For
ProShares00 3,7550Abstain
PENN SERIES FUNDS INC00 3,6000Abstain
SEI2,3000 00For

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

6. Election of Directors: Paul R. Biondi

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

65% Majority: yes · of votes cast

FOR 65%WITHHELD 35%
FOR: 53,477,829WITHHELD: 29,111,829

SERES THERAPEUTICS INC.’s own tally for this item (“Elect Director: Paul R. Biondi”): 53,477,829 for, 29,111,829 withheld, per its Form 8-K filed 2024-04-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 151,009,462 outstanding shares: 35% for, 19% withheld (54.7% of the company cast a for/withheld vote).

The 32 asset managers below cast 100% of the shares they voted on this item FOR (6,981,326 for, 0 against).

FOR 38%ABSTAIN 62%
FOR: 6,981,326 (38.2%)ABSTAIN: 11,272,488 (61.8%)
Largest asset managers voting on “Election of Directors: Paul R. Biondi” at SERES THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity1,018,2480 10,615,5350Abstain
Vanguard4,073,1900 00For
BlackRock1,168,1140 00For
Charles Schwab390,8530 00For
SIT MUTUAL FUNDS INC00 246,7750Abstain
Equitable39,4640 127,6600Abstain
BRIDGEWAY FUNDS INC00 150,0000Abstain
Lincoln Financial80,0000 00For
QUANTITATIVE MASTER SERIES LLC54,7300 00For
Principal Exchange-Traded Funds00 48,9170Abstain
Northern Trust43,6230 00For
Pacific Life34,8780 00For
Voya33,0610 00For
Bridge Builder Trust24,4680 00For
John Hancock00 18,4420Abstain
DWS00 15,0650Abstain
Victory Capital00 12,9480Abstain
Principal00 12,1590Abstain
AIG/SunAmerica00 11,3650Abstain
State Street8,4620 00For
Calvert00 8,0330Abstain
Morgan Stanley3,8660 00For
ProShares00 3,7550Abstain
PENN SERIES FUNDS INC3,6000 00For
SEI2,3000 00For

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

7. Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 100,843,550AGAINST: 2,910,775

SERES THERAPEUTICS INC.’s own tally for this item (“Item 2 - Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.”): 100,843,550 for, 2,910,775 against, per its Form 8-K filed 2024-04-08 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 151,009,462 outstanding shares: 67% for, 2% against (69% of the company cast a for/against vote).

The 32 asset managers below cast 99.1% of the shares they voted on this item FOR (18,095,503 for, 158,311 against).

FOR 99.1%
FOR: 18,095,503 (99.1%)AGAINST: 158,311 (0.9%)
Largest asset managers voting on “Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for ” at SERES THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity11,633,7830 00For
Vanguard4,073,1900 00For
BlackRock1,168,1140 00For
Charles Schwab390,8530 00For
SIT MUTUAL FUNDS INC246,7750 00For
Equitable167,1240 00For
BRIDGEWAY FUNDS INC0150,000 00Against
Lincoln Financial80,0000 00For
QUANTITATIVE MASTER SERIES LLC54,7300 00For
Principal Exchange-Traded Funds48,9170 00For
Northern Trust43,6230 00For
Pacific Life34,8780 00For
Voya33,0610 00For
Bridge Builder Trust24,4680 00For
John Hancock18,4420 00For
DWS15,0650 00For
Victory Capital12,9480 00For
Principal12,1590 00For
AIG/SunAmerica11,3650 00For
State Street8,4620 00For
Calvert08,033 00Against
Morgan Stanley3,8660 00For
ProShares3,7550 00For
PENN SERIES FUNDS INC3,6000 00For
SEI2,3000 00For

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

Largest SERES THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of SERES THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 151,009,462 shares outstanding at the time of that meeting.

Top SERES THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 19.87%
2Flagship Pioneering Inc. 15.31%
3Vanguard 2.78%
4Hudson Bay Capital Management LP 2.68%
5BlackRock 2.31%
6GEODE CAPITAL MANAGEMENT, LLC 0.74%
7State Street 0.70%
8Charles Schwab 0.52%
9Woodline Partners LP 0.46%
10MELLON INVESTMENTS Corp 0.32%

Reported SERES THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

SERES THERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
Entities affiliated with Flagship Pioneering 15.31% DEF14A
FMR LLC 12.84% DEF14A
Nestlé S.A. 5.03% DEF14A
BlackRock, Inc. 4.86% DEF14A
Eric D. Shaff 1.74% DEF14A
Geode Capital 1.41% 13F
State Street 1.29% 13F
Millennium Management 0.68% 13F
Northern Trust 0.52% 13F
Charles Schwab 0.49% 13F

Percentages above are of 151,009,462 shares outstanding, as reported by SERES THERAPEUTICS INC. on its Form 10-K dated 2024-03-01 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SERES THERAPEUTICS INC.’s 10-K dated 2024-03-01. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At SERES THERAPEUTICS INC.'s shareholder meeting held 2024-04-04, in the 2023-2024 proxy season, 112 asset managers reported how they voted on 7 ballot items in their SEC Form N-PX filings, covering 865 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory (non- binding) basis, of the compensation of our named executive… — FOR was 65% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SERES THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-04-08.

SERES THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page).